Ocarocoxib

Ocarocoxib

Every year, nearly a half million surgical patients develop an opioid addiction as a direct result of misuse and overuse of opioid therapy. To address the relentless opioid epidemic, Ocaro Pharmaceuticals is developing Ocarocoxib, intended to be an opioid-sparing COX-2 selective NSAID, for evaluation by the FDA as a safe, effective, non-habit-forming treatment of acute post-operative pain.

Development Timeline

Indication

Early Discovery

Late Discovery

Pre-clinical Development
Phase 1 Human Safety
Phase 2 Human Efficacy Dose Ranging

Phase 3
FDA
Approval

OCAROCOXIB
  • Through an FDA-regulated Investigational New Drug (IND) development program, led by a team of nationally recognized researchers, Ocaro aims to bring to market Ocarocoxib, an alternative to opioid prescriptions for post-surgical pain.

  • The Ocaro team has been granted permission by the FDA to initiate our first human clinical trial, which we are actively planning with our collaborators.

  • Ocarocoxib targets the COX2 receptor, a key component of the pain biological pathway, with a new class of chemistry. The new drug is metabolized in a way that may provide additional safety benefits.

Ocarocoxib

Indication
100%
Early Discovery
100%
Late Discovery
100%
Pre-clinical Development
58%
Phase 1 Human Safety
Phase 2 Human Efficacy Dose Ranging
Phase 3 FDA Approval

Need help? Call our award-winning support team at (XXX) XXX-XXX

Copyright 2024 © All Rights Reserved.